Simply Wall St.
What New Catalysts Are Shifting the Pulmonx Story for Investors
📊
AI Sentiment
Positive
7/10
- Home
- LUNG
LUNG
Pulmonx Corporation
as of 12-12-2025 1:57pm EST
$2.56
+$0.05
+2.04%
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.
Chart Type:
Time Range:
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | REDWOOD CITY |
| Market Cap: | 63.6M | IPO Year: | 2020 |
| Target Price: | $6.81 | AVG Volume (30 days): | 1.1M |
| Analyst Decision: | Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.31 - $9.37 | Next Earning Date: | 11-12-2025 |
| Revenue: | $91,664,000 | Revenue Growth: | 15.59% |
| Revenue Growth (this year): | 9.21% | Revenue Growth (next year): | 5.03% |
AI-Powered LUNG Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 19 hours ago
AI Recommendation
hold
Model Accuracy: 67.12%
67.12%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Pulmonx Corporation (LUNG)
Florin Daniel P
Sell
Director
LUNG Dec 8, 2025
Avg Cost/Share
$1.99
Shares
23,321
Total Value
$46,408.79
Owned After
93,910
SEC Form 4
Rose Geoffrey Beran
Sell
CHIEF COMMERCIAL OFFICER
LUNG Dec 1, 2025
Avg Cost/Share
$1.57
Shares
6,322
Total Value
$9,925.54
Owned After
375,845
French Glendon E. III
Sell
President and CEO
LUNG Dec 1, 2025
Avg Cost/Share
$1.57
Shares
8,805
Total Value
$13,823.85
Owned After
283,605
Lehman David Aaron
Sell
GENERAL COUNSEL
LUNG Dec 1, 2025
Avg Cost/Share
$1.57
Shares
10,278
Total Value
$16,136.46
Owned After
262,294
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Florin Daniel P | LUNG | Director | Dec 8, 2025 | Sell | $1.99 | 23,321 | $46,408.79 | 93,910 | |
| Rose Geoffrey Beran | LUNG | CHIEF COMMERCIAL OFFICER | Dec 1, 2025 | Sell | $1.57 | 6,322 | $9,925.54 | 375,845 | |
| French Glendon E. III | LUNG | President and CEO | Dec 1, 2025 | Sell | $1.57 | 8,805 | $13,823.85 | 283,605 | |
| Lehman David Aaron | LUNG | GENERAL COUNSEL | Dec 1, 2025 | Sell | $1.57 | 10,278 | $16,136.46 | 262,294 |
Latest Pulmonx Corporation News
LUNG Breaking Stock News: Dive into LUNG Ticker-Specific Updates for Smart Investing
Compare LUNG vs Leading Stocks
See how LUNG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "LUNG Pulmonx Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.